Skip to content

BrainScape Medical makes strides in long-term brain monitoring

Life sciences

21 January 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials. BrainScape Medical’s Platform combines cutting-edge brain monitoring with therapeutic interventions, offering new hope for managing neurological disorders through personalized care. | © BrainScape Medical

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

Founded in late 2024, BrainScape Medical aims to revolutionize the diagnosis, monitoring, and treatment of neurological disorders. Through an exclusive license agreement with the Wyss Center for Bio and Neuro Engineering, BrainScape has acquired the Epios® technology (now called Brainscape Platform), a cutting-edge implantable device developed in Geneva. This innovation addresses the challenges of capturing continuous, long-term brain activity data—critical for managing complex conditions like epilepsy and dementia, which affect millions worldwide.

The BrainScape Platform combines monitoring and therapeutic intervention into a single, minimally invasive system. By providing real-time insights and enabling neurofeedback and stimulation, the technology aims to improve outcomes for patients while setting a new standard in personalized care.

The first-in-human trial of the Brainscape Platform demonstrated the device’s safety and efficacy. Conducted on eight patients over nine days, the study successfully recorded long-term EEG signals with full head coverage. Published in leading medical journals, these results highlight the BrainScape Platform as a groundbreaking solution for brain activity detection, paving the way for expanded clinical applications and personalized therapeutic interventions.

Advancing neurology through strategic leadership FDA recognition and Swiss innovation support

In the company’s press release, Dr. Erwin Böttinger, Director of the Wyss Center, emphasized the collaboration’s potential: “The strides made by BrainScape Medical reflect our commitment to translating innovative research into real-world solutions that improve lives.”

The BrainScape Platform has received the U.S. FDA’s Breakthrough Device Designation for its potential to address unmet needs in managing pharmacoresistant epilepsy and infrequent seizure episodes. This recognition will streamline regulatory processes, expediting patient access to the technology in the U.S. market.

To support its growth, BrainScape Medical has appointed Dr. Laura Johnson as CEO. With over 20 years of medtech leadership experience, Dr. Johnson brings a vision for advancing the neuro-therapeutics market. She aims to lead BrainScape through a Series A funding round, support FDA approval, and explore new applications for the BrainScape Platform.

Supported by GGBa and the Office Cantonal de l’Économie et de l’Innovation (OCEI) in its establishment, BrainScape Medical is headquartered at the Campus Biotech in Geneva, leveraging the region’s robust innovation ecosystem. With its technology and a clear roadmap for growth, the company is on track to transform the treatment of neurological disorders and improve the standard of care for millions of people worldwide.